Awiqli Cost & Insurance: What You'll Pay for Once-Weekly Insulin in 2026

The FDA approval of Awiqli (insulin icodec) on March 26, 2026, introduced the first once-weekly basal insulin for adults with type 2 diabetes. Manufactured by Novo Nordisk and delivered via a pre-filled FlexTouch pen at 700 units/mL, Awiqli promises to reduce injection burden from 365 injections per year to just 52. But how much will it cost, and will your insurance cover it? This guide breaks down pricing, coverage expectations, savings programs, and practical tips for managing out-of-pocket expenses.

Estimated List Price

Awiqli's estimated wholesale acquisition cost falls in the range of $500 to $700 per month, positioning it competitively with premium daily basal insulins. Novo Nordisk has signaled it will price Awiqli to encourage adoption rather than as a super-premium product. For context, daily basal insulins carry the following approximate monthly list prices:

• Lantus (insulin glargine U-100): $300–$400/month
• Tresiba (insulin degludec): $400–$500/month
• Toujeo (insulin glargine U-300): $400–$500/month
• Basaglar (biosimilar glargine): $200–$300/month

While Awiqli's list price is higher than some daily options, the total cost of care may be comparable or even lower when factoring in reduced needle and syringe costs, fewer pharmacy visits, and improved adherence rates that reduce costly complications.

Insurance Coverage

Most commercial insurance plans are expected to add Awiqli to their formularies in 2026, though coverage will vary by plan and pharmacy benefits manager (PBM). Key considerations:

• Prior authorization: Many plans will require prior authorization, typically documenting that the patient has type 2 diabetes and is currently on or appropriate for basal insulin therapy.
• Formulary tier: Awiqli may be placed on a preferred or non-preferred brand tier depending on the PBM's negotiations with Novo Nordisk. Patients should check with their insurer for tier placement.
• Step therapy: Some plans may require patients to try a daily basal insulin first before approving Awiqli, though adherence challenges with daily dosing can often support an exception request.

Medicare Part D: The $35 Insulin Cap

Under the Inflation Reduction Act (IRA), Medicare Part D beneficiaries benefit from a $35 per month cap on insulin copays, which applies to Awiqli. This is a significant advantage for Medicare patients — regardless of Awiqli's list price, the maximum monthly out-of-pocket cost is capped at $35. Combined with the IRA's $2,000 annual out-of-pocket maximum for Part D, Awiqli becomes financially accessible for the Medicare population, which represents a large share of type 2 diabetes patients.

Novo Nordisk Savings Programs

Novo Nordisk offers multiple financial assistance pathways for Awiqli:

• Awiqli Savings Card: Commercially insured patients may pay as little as $25 per month with the manufacturer savings card. Maximum annual benefit limits apply; check the Novo Nordisk patient portal for current terms.
• Novo Nordisk Patient Assistance Program (PAP): Uninsured patients meeting income criteria (typically ≤400% of federal poverty level) can receive Awiqli at no cost through the PAP. Applications are processed through NovoCare.
• Immediate Supply Program: Patients awaiting insurance approval can receive a temporary free supply to prevent treatment gaps.

Cost Comparison: Awiqli vs. Daily Insulin

Insulin	Dosing	Est. Monthly List	Injections/Year	Needles Needed	Savings Card Copay
Awiqli	Once weekly	$500–$700	52	52	As low as $25/mo
Lantus	Once daily	$300–$400	365	365	$0–$99/mo
Tresiba	Once daily	$400–$500	365	365	As low as $25/mo
Toujeo	Once daily	$400–$500	365	365	$0–$99/mo
Basaglar	Once daily	$200–$300	365	365	Varies

Note: Needle and sharps disposal costs add approximately $50–$150/year for daily insulin users. Awiqli reduces this expense by ~85%.

The Hidden Savings of Once-Weekly Dosing

Cost comparisons based on list price alone miss important factors that favor Awiqli:

• Fewer needles and pen tips: 52 vs. 365 per year — a meaningful cost and waste reduction
• Improved adherence: Studies consistently show that less frequent dosing improves adherence. For insulin, missed doses lead to poor glycemic control, which increases the risk of costly complications including hospitalizations, diabetic neuropathy, and cardiovascular events
• Fewer pharmacy interactions: Monthly refills are simpler to manage with a weekly insulin
• Reduced sharps waste: Fewer needles mean fewer disposal containers and less environmental impact
• Caregiver burden: For patients who rely on caregivers for injections, reducing frequency from daily to weekly is a substantial quality-of-life improvement

Tips for Reducing Your Out-of-Pocket Cost

• Apply for the savings card immediately when your provider writes the prescription — don't wait for the pharmacy to fill it first
• Ask your endocrinologist for a letter of medical necessity documenting adherence challenges with daily insulin to support prior authorization
• Check NovoCare.com for the latest financial assistance options and eligibility criteria
• Compare specialty vs. retail pharmacies — mail-order pharmacy services sometimes offer better pricing for brand insulins
• If on Medicare, confirm your plan covers Awiqli under the $35 insulin cap before filling
• Appeal any denial — documentation of missed daily doses, A1C elevation, or injection site complications strengthens your case

The Bottom Line

Awiqli's list price is higher than generic and biosimilar daily insulins but competitive with premium brands like Tresiba. With the Medicare $35 insulin cap, manufacturer savings cards, and patient assistance programs, most patients can access Awiqli at a manageable cost. The hidden savings from improved adherence and reduced supply needs further close the gap. For clinical details on how Awiqli compares to daily insulin, see our Awiqli vs. daily insulin comparison and switching guide.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication.